文献速递妇科

rucaparib与安慰剂维持治疗转移性和复发性子宫内膜癌的II期随机双盲研究

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2025-07-22

这项多机构、双盲、安慰剂对照的随机II期试验纳入79例III期、IV期或复发性子宫内膜癌患者,按1:1随机分配接受口服rucaparib 600 mg每日两次或安慰剂维持治疗。rucaparib组中位无进展生存期28.1个月,安慰剂组8.7个月(HR 0.45,95%CI 0.24-0.87,p=0.02);总生存期rucaparib组未达到,安慰剂组28.4个月(HR 0.43,95%CI 0.18-1.05)。作者认为rucaparib维持治疗显示出有前景的活性,值得进一步开展III期评估。

要点

  • rucaparib组中位无进展生存期28.1个月 vs 安慰剂组8.7个月,HR 0.45(95%CI 0.24-0.87,p=0.02)。
  • 总生存期rucaparib组未达到 vs 安慰剂组28.4个月,HR 0.43(95%CI 0.18-1.05)。
  • rucaparib组最常见≥3级不良事件为贫血、乏力和中性粒细胞减少。

核心结论

  • 维持使用rucaparib在完成一线或二线化疗后显示出有前景的活性,值得进一步开展III期评估。
  • 不良事件与rucaparib在其他肿瘤类型中的既往使用一致,未发现新的安全性信号。

研究设计与样本

  • 多机构、双盲、安慰剂对照、随机II期试验。
  • 纳入III期、IV期或复发性子宫内膜癌患者,为完成一线或二线化疗后有可测量或不可测量病灶者。
  • 按1:1随机分配接受口服rucaparib 600 mg每日两次或安慰剂,直至疾病进展。
  • 共79例患者随机,rucaparib组39例,安慰剂组40例。
  • 主要终点为无进展生存期,次要终点为总生存期和安全性,探索性终点为肿瘤分子谱和转录组谱相关反应。

主要发现

  • rucaparib组中位无进展生存期28.1个月 vs 安慰剂组8.7个月,HR 0.45(95%CI 0.24-0.87,p=0.02)。
  • rucaparib组中位总生存期未达到 vs 安慰剂组28.4个月,HR 0.43(95%CI 0.18-1.05)。
  • rucaparib组最常见≥3级不良事件为贫血、乏力和中性粒细胞减少。
  • 转录组评估显示p53活性缺失与rucaparib反应改善相关。
  • 传统DNA修复同源重组生物标志物与反应不相关。

关键数值与推荐

  • rucaparib用法:口服600 mg每日两次,直至疾病进展。
  • 随机比例1:1,rucaparib组39例,安慰剂组40例。

临床怎么用

  • 作者认为,完成一线或二线化疗后维持使用rucaparib显示出有前景的活性,值得进一步开展III期评估。

局限性

  • 作者结论指出该结果值得进一步开展III期评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rucaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor with proven efficacy in multiple tumor types. The efficacy of PARP inhibition in endometrial cancer remains unclear. METHODS: We conducted a multi-institutional, double-blind, placebo-controlled, randomized phase II trial. Eligible patients had stage III, IV or recurrent endometrial cancer. We assigned patients with measurable, or non-measurable disease following completion of first- or second-line chemotherapy in a 1:1 ratio to receive oral rucaparib (600 mg twice daily) or placebo until disease progression. The primary endpoint was progression-free survival. Secondary outcomes were overall survival and safety. Exploratory outcomes evaluated response in relation to tumor molecular profiles and transcriptomic profiles. RESULTS: 79 patients were randomized, 39 received rucaparib and 40 received placebo. Median progression free survival was 28.1 months in the rucaparib arm compared to 8.7 months in the placebo group, hazard ratio 0.45; (95 % confidence interval [CI] (0.24-0.87); p = 0.02). Median overall survival was not reached in the rucaparib arm compared to 28.4 months in the placebo arm; hazard ratio 0.43 (95 % CI, 0.18-1.05). In patients treated with rucaparib, the most common grade ≥ 3 adverse events were anemia, fatigue, and neutropenia. Loss of p53 activity correlated to improved rucaparib response by transcriptomic evaluation. Traditional DNA repair homologous recombination biomarkers did not correlate with response. CONCLUSIONS: Maintenance use of rucaparib after first- or second-line chemotherapy demonstrates promising activity and warrants further evaluation in a phase III evaluation. Adverse events were aligned with previous use of rucaparib in other tumor types and no new safety signals were identified. CLINICALTRIALS: gov identifier: NCT03617679.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Corr BR, Haggerty A, Gysler SM, et al. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025. PMID: 40700852. doi:10.1016/j.ygyno.2025.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。